Hotline 24/7: 0909384389

Share links:

TVT 2022: Late-breaking data point to favourable haemodynamic performance of latest-generation TAVI device

Ngày 21/06/2022 08:10 | Lượt xem: 783

Transcatheter aortic valve implantation (TAVI) with the Acurate neo2 (Boston Scientific) device was associated with a lower prevalence of moderate or severe paravalvular aortic regurgitation (AR) and more patients with no or trace paravalvular AR compared with an earlier-generation device—a difference that was particularly evident in patients with heavy aortic valve calcification.

This was the conclusion of Andrea Scotti (Montefiore Medical Center, New York, USA), who delivered analysis of data from the NEOPRO and NEOPRO-2 registries during a late-breaking trial session at TVT 2022 (The Structural Heart Summit, 8–10 June, Chicago, USA), which was simultaneously published in EuroIntervention. The analysis looked at haemodynamic performance and clinical outcomes of TAVI with the latest-generation Acurate neo2 device.

The investigator-driven study used retrospective registry data from a total of 2,026 patients from 34 European centres comparing outcomes with the previous-generation Acurate neo valve from the NEOPRO Registry (1,263 patients from 18 centres) with those of the Acurate neo2 valve from the NEOPRO2 Registry (763 patients from 16 centres).

Key findings included a significant reduction in moderate or severe paravalvular aortic regurgitation (PAR) for the Acurate neo2 valve (2% vs. 5% with Acurate neo; p<0.001), contributing to the study meeting its primary endpoint with a higher VARC-3 intended valve performance (96% vs. 90%, p<0.001).

Investigators also found a significant reduction in mild PAR with patients receiving the Acurate neo2 valve, demonstrating a greater proportion of none/trace PAR (38% vs. 59% with Acurate neo, p<0.001). Furthermore, similar 30-day results (secondary endpoint) for VARC-3 technical success (Acurate neo2 93% vs. Acurate neo 91%, p=0.117), device success (Acurate neo2 84% vs. Acurate neo 81%, p=0.119) and one-year survival after TAVI (Acurate neo2 90% vs Acurate neo 87%; p=0.14), were also reported.

The analysis presented by Scotti at TVT 2022 follows closely behind the release of further data looking at Acurate neo2 at EuroPCR 2022 (17–20 May, Paris, France).

At the EuroPCR meeting Christopher Meduri (Karolinska Institut, Stockholm, Sweden) presented findings from the Neo-Align Study, a single-centre study of 170 patients who underwent TAVI with the Acurate neo2 valve using a novel implant technique to attempt commissural alignment of the prosthetic and native valves. The study demonstrated that commissural alignment can be achieved safely, effectively and quickly, with data demonstrating that 97% of patients had no significant misalignment (80% non; 17% mild; 1.2% moderate; 1.8% severe) and the average alignment time of 92 seconds had a minimal impact on procedure duration.

Post-procedure and 30-day safety events were consistent with expected TAVI complication rates, and small manipulations of the delivery system in the ascending aorta did not adversely impact safety outcomes, investigators reported.

Also at EuroPCR, Andrea Buono (Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy) reported findings from the ITAL-neo registry, a two-arm, retrospective registry of 900 patients from 13 Italian centres, which it was reported, demonstrated superior performance of the Acurate neo2 valve compared with the previous-generation Acurate neo valve in minimising paravalvular leak (PVL).

The study, published simultaneously in JACC: Cardiovascular Interventions, met its primary endpoint with a three-fold reduction in more-than-mild paravalvular aortic regurgitation with the Acurate neo2 valve (11.2% for Acurate neo vs. 3.5% for Acurate neo2). The data also demonstrated a numerically higher in-hospital technical device success rate and improved success and safety outcomes at 90 days (secondary endpoints) for the Acurate neo2 valve.

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support